Search Results

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.

Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.

SK Life Science, Inc. today announced the U.S. Food and Drug Administration (FDA) approved two new administration options of XCOPRI® (cenobamate tablets) CV, an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.

SK Life Science, Inc. today announced the schedule for two oral and six poster presentations at the American Academy of Neurology (AAN) Annual Meeting taking place April 13–18, 2024, virtually and in-person in Denver, Colorado.

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) today announced that it will release financial results for the first quarter ended March 31, 2023, before the stock market opens on Monday, May 15, 2023.